A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)

Still's Disease, Adult-Onset Clinical Trial

— anaSTILLs  

Official title:

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of 2 Dose Levels of Subcutaneous Anakinra (Kineret®) in Patients With Still's Disease (SJIA and AOSD)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03265132
• Other study ID #: Sobi.ANAKIN-301
• Status: Terminated
• Phase: Phase 3
• Start date: September 26, 2017
• Est. completion date: May 23, 2019

Study information

• Verified date: June 2021
• Source: Swedish Orphan Biovitrum
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to demonstrate the efficacy and to evaluate the safety, pharmacokinetics (PK) and immunogenicity of anakinra in patients with newly diagnosed Still's disease, including SJIA (Systemic juvenile idiopathic arthritis) and AOSD (Adult-onset Still's disease).

Description:

The study consists of a 12-week, randomized, double-blind, placebo controlled period with two dose levels of anakinra and a 4-week safety follow-up after last dose of investigational medicinal product (IMP). The primary endpoint will be evaluated at Week 2. Sustained efficacy and time to study drug discontinuation will be evaluated during the full study period. A screening visit is optional and may be done to identify patients that could be suitable for the study. During the study 6 visits and 2 telephone contacts are scheduled i.e., Day 1 (baseline visit), Day 4Tel, Week 1, Week 2, Week 4, Week 8, Week 12 and Week 16Tel (End of Study). Patients will be randomly assigned to study drug, after they meet all of the inclusion criteria and none of the exclusion criteria. Patients will receive treatment for 12 weeks, either anakinra or placebo. Patients will be randomized to anakinra in a dose of either 2 or 4 mg/kg/day, with a maximum dose of 100 or 200 mg once daily, respectively. Patients will be randomized to placebo with corresponding volumes for each of the two anakinra dose levels.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 13
• Est. completion date: May 23, 2019
• Est. primary completion date: February 13, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Signed informed consent.

2. Male and female patients with a body weight = 10 kg.

3. Diagnosis of Still's disease.

4. If currently on glucocorticoid treatment, a stable dose for at least 1 week prior to randomization.

5. If currently on methotrexate treatment, a stable dose for at least 8 weeks prior to randomization.

6. Active disease.

7. Female patients of childbearing potential must use an effective method of contraception during the study (abstinence being a possible option) as well as present a negative pregnancy test prior to randomization.

8. Negative interferon-gamma release assay or Purified protein derivative ( PPD) test within 2 months prior to randomization. If not available, a test should be performed at day of randomization.

Exclusion Criteria:

1. Diagnosis of Still's disease more than 6 months prior to randomization.

2. Previous randomization into this study.

3. Participation in another concurrent clinical interventional study within 30 days of randomization.

4. Treatment with an investigational drug within 5 half-lives prior to randomization.

5. Previous or current treatment with anakinra, canakinumab or any other IL-1 inhibitor.

6. Use of the following therapies prior to randomization:

• Narcotic analgesics within 24 hours prior to randomization.
• Dapsone or etanercept within 3 weeks prior to randomization.
• Intraarticular, intramuscular or intravenous administration of glucocorticoids or intravenous immunoglobulin (Ig) within 4 weeks prior to randomization.
• Intravenous Ig with proven Still's disease modifying effect, leflunomide, infliximab or adalimumab within 8 weeks prior to randomization.
• Thalidomide, cyclosporine, mycophenolate mofetil, 6-mercaptopurine, azathioprine, cyclophosphamide, chlorambucil or any other immunosuppressant within 12 weeks prior to randomization.
• Tocilizumab within 12 weeks prior to randomization or any other immunomodulatory medication within 4 half-lives prior to randomization
• Rituximab within 26 weeks prior to randomization.

7. Live vaccines within 1 month prior to randomization.

8. Known presence or suspicion of active, chronic or recurrent bacterial, fungal or viral infections, including tuberculosis, HIV infection or hepatitis B or C infection.

9. Clinical evidence of liver disease or liver injury.

10. Presence of severe renal function impairment.

11. Presence of neutropenia.

12. Presence or suspicion of MAS at baseline.

13. A diagnosis of MAS within the last 2 months prior to randomization.

14. History of malignancy within 5 years.

15. Known hypersensitivity to E coli-derived proteins, or any components of Kineret® (anakinra).

16. Pregnant or lactating women.

17. Foreseeable inability to cooperate with given instructions or study procedures.

18. Presence of any medical or psychological condition or laboratory result that in the opinion of the investigator can interfere with the patient's ability to comply with the protocol requirements or makes the patient not appropriate for inclusion to the study and treatment with IMP.

Related Conditions & MeSH terms

• Arthritis, Juvenile
• Still's Disease, Adult-Onset
• Still's Disease, Juvenile-Onset

Intervention

Biological:
• anakinra
sub cutaneous injection

Drug:
• Placebo
sub cutaneous injection

Locations

Country	Name	City	State
Canada	University of Calgary	Calgary
Canada	University of Calgary - Alberta Children's Hospital	Calgary
Canada	The Hospital for Sick Children	Toronto
United States	University of Michigan	Ann Arbor	Michigan
United States	The Children's Hospital Colorado	Aurora	Colorado
United States	Attune Health	Beverly Hills	California
United States	University of Alabama Birmingham	Birmingham	Alabama
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Boston Children's Hospital	Boston	Massachusetts
United States	University of Vermont Medical Center	Burlington	Vermont
United States	UNC Hospitals	Chapel Hill	North Carolina
United States	MetroHealth System	Cleveland	Ohio
United States	Nationwide Children's Hospital	Columbus	Ohio
United States	Baylor Research Institute	Dallas	Texas
United States	Univ of TX Southwestern Medical Center Dallas - Texas Scottish Rite Hospital for Children	Dallas	Texas
United States	Duke Children's Hospital and Health Center	Durham	North Carolina
United States	Saint Paul Rheumatology	Eagan	Minnesota
United States	University of Florida	Gainesville	Florida
United States	Hackensack University Medical Center	Hackensack	New Jersey
United States	Texas Children's Hospital	Houston	Texas
United States	University of Iowa Hospitals and Clinics	Iowa City	Iowa
United States	Children's Mercy Hospital and Clinics	Kansas City	Kansas
United States	University of Louisville School of Medicine Research Foundation	Louisville	Kentucky
United States	Nicklaus Children's Hospital	Miami	Florida
United States	University of Miami	Miami	Florida
United States	Medical College of Wisconsin	Milwaukee	Wisconsin
United States	University of Minnesota	Minneapolis	Minnesota
United States	Monroe Carell Jr. Children's Hospital at Vanderbilt	Nashville	Tennessee
United States	Columbia University Medical Center	New York	New York
United States	Hospital for Special Surgery	New York	New York
United States	Children's Hospital of Pittsburgh of UPMC	Pittsburgh	Pennsylvania
United States	Virginia Commonwealth University	Richmond	Virginia
United States	Saint Louis University	Saint Louis	Missouri
United States	University of Utah Hospitals and Clinics	Salt Lake City	Utah
United States	University of Texas Health Science Center at San Antonio	San Antonio	Texas
United States	Rady Children's Hospital & Health Center	San Diego	California
United States	University of Washington	Seattle	Washington
United States	Institute for Rheumatic and Autoimmune Diseases	Summit	New Jersey
United States	Wake Forest Baptist Brenner Medical Center	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Swedish Orphan Biovitrum

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of ACR30 Responders With Absence of Fever Attributable to the Disease During the 7 Days Preceding Week 2.	ACR30 response is defined as an improvement of = 30% from baseline in at least 3 of any 6 variables listed below. Also no more than 1 of the 6 variables may worsen by >30% from baseline. (ACR: American College of Rheumatology); Physician global assessment of disease activity - Assessed on a Visual Analogue Scale (VAS) from no disease activity (0 mm) to very severe disease activity (100 mm).; Patient/parent global assessment of overall well-being - Assessed on a VAS from very well (0 mm) to very poor (100 mm).; Number of joints with active arthritis.; Number of joints with limitation of motion.; Assessment of physical function - Patient Reported Outcome instruments : Childhood Health Assessment Questionnaire (CHAQ) /Stanford Health Assessment Questionnaire (SHAQ).; C-Reactive Protein (CRP) (mg/L).	Week 2
Secondary	Proportion of ACR30 Responders With Absence of Fever During 24 Hours Preceding Week 1.	ACR30 response is defined as an improvement of = 30% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome measure. Also no more than 1 of the 6 variables may worsen by >30% from baseline.	Week 1
Secondary	Proportion of ACR50 Responders With Absence of Fever During 24 Hours Preceding Week 1.	ACR50 response is defined as an improvement of = 50% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome measure. Also no more than 1 of the 6 variables may worsen by >30% from baseline.	Week 1
Secondary	Proportion of ACR70 Responders With Absence of Fever During 24 Hours Preceding Week 1.	ACR70 response is defined as an improvement of = 70% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome measure. Also no more than 1 of the 6 variables may worsen by >30% from baseline.	Week 1
Secondary	Proportion of ACR90 Responders With Absence of Fever During 24 Hours Preceding Week 1.	ACR90 response is defined as an improvement of = 90% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome measure. Also no more than 1 of the 6 variables may worsen by >30% from baseline.	Week 1
Secondary	Proportion of ACR50 Responders With Absence of Fever During 7 Days Preceding Week 2.	ACR50 response is defined as an improvement of = 50% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome measure. Also no more than 1 of the 6 variables may worsen by >30% from baseline.	Week 2
Secondary	Proportion of ACR70 Responders With Absence of Fever During 7 Days Preceding Week 2.	ACR70 response is defined as an improvement of = 70% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome. Also no more than 1 of the 6 variables may worsen by >30% from baseline.	Week 2
Secondary	Proportion of ACR90 Responders With Absence of Fever During 7 Days Preceding Week 2.	ACR90 response is defined as an improvement of = 90% from baseline in at least 3 of any 6 variables listed in the description of the primary outcome . Also no more than 1 of the 6 variables may worsen by >30% from baseline.	Week 2
Secondary	Proportion of Responders in Physician Global Assessment of Disease Activity.	Assessed on a VAS from no disease activity (0 mm) to very severe disease activity (100 mm). Response is defined as an improvement of = 30%, 50%, 70% and 90% from baseline. Only improvement of =90% at Week 2 reported here.	Week 2
Secondary	Proportion of Responders in Patient/Parent Global Assessment of Overall Well-being.	Assessed on a VAS from very well (0 mm) to very poor. (100 mm). Response is defined as an improvement of = 30%, 50%, 70% and 90% from baseline.Only improvement of =90% at Week 2 reported here.	Week 2
Secondary	Proportion of Responders in Number of Joints With Active Arthritis.	Response is defined as an improvement of = 30%, 50%, 70% and 90% from baseline.Only improvement of =90% at Week 2 reported here.	Week 2
Secondary	Proportion of Responders in Number of Joints With Limitation of Motion.	Response is defined as an improvement of = 30%, 50%, 70% and 90% from baseline.Only improvement of =90% at Week 2 reported here.	Week 2
Secondary	Proportion of Responders in Assessment of Physical Function (CHAQ/SHAQ).	Childhood Health Assessment Questionnaire (CHAQ) and Stanford Health Assessment Questionnaire (SHAQ) assess physical and functional status (see Clinical protocol section 6.5.4.1.5). Response is defined as an improvement of = 30%, 50%, 70% and 90% from baseline. Only improvement of =90% at Week 2 reported here.	Week 2
Secondary	Proportion of Responders in CRP (mg/L).	Response is defined as an improvement of = 30%, 50%, 70% and 90% from baseline. Only improvement of =90% at Week 2 reported here.	Week 2
Secondary	Proportion of Patients With Absence of Fever During the 7 Days Preceding Week 2.	Proportion of patients with absence of fever during the 7 days preceding Week 2.	Week 2
Secondary	Proportion of Patients With Absence of Fever During the 24 Hours Preceding Week 1.	Absence of fever during the 24 hours preceding week 1.	Week 1
Secondary	Change From Baseline in Physician Global Assessment of Disease Activity at Week 1.	Change from baseline in Physician global assessment of disease activity measured on a VAS 0 (very well)-100 (very poor) at Week 1.	Day 1 and Week 1
Secondary	Change From Baseline in Patient/Parent Global Assessment of Overall Well-being at Week 1.	Change from baseline in patient/parent global assessment of overall well-being measured on a VAS 0 (very well)-100 (very poor) at Week 1.	Day 1 and Week 1
Secondary	Change From Baseline in CRP.	Change from baseline in C-Reactive Protein (CRP). CRP is measured in mg/L.	Day 1 and Week 1
Secondary	Proportion of Patients With Sustained ACR30, ACR50, ACR70 and ACR90 Response.	Proportion of patients that still meet the corresponding week 2 response with absence of fever in the preceding 7 days. Only the strictest criteria, ACR90, is reported here.	Week 12
Secondary	Proportion of Patients With Sustained ACR30, ACR50, ACR70 and ACR90 Response in Relation to Glucocorticoid Tapering.	Please note no patients were treated with any systemic glucocorticoids at randomization. Hence no results available.	Week 2, Week 4, Week 8 and Week 12
Secondary	Proportion of Patients With Absence of Rash.	Absence of rash is evaluated 24 hours preceding Week 1 and 7 days preceding Week 2, Week 4, Week 8 and Week 12. Only data at Week 2 reported here.	Week 2
Secondary	Change From Baseline in CRP.	Change from baseline in CRP. Results at Week 2 reported here.	Week 2
Secondary	Change From Baseline in Hemoglobin (Hb). Results at Week 2 Reported Here.	Change from baseline in Hemoglobin (Hb). Results at Week 2 reported here.	Week 2
Secondary	Change From Baseline in Platelet Count.	Change from baseline in platelet count. Results at Week 2 reported here.	Week 2
Secondary	Change From Baseline in Ferritin.	Change from baseline in ferritin. Results at Week 2 reported here.	Week 2
Secondary	Change From Baseline in Patient/Parent Global Assessment of Disease Related Pain.	Assessed on a VAS from no pain (0 mm) to very severe pain (100 mm).	Week 2
Secondary	Time to Study Drug Discontinuation for Any Reason.	Time to study drug discontinuation was analyzed using Kaplan-Meier curves. Number of patients with premature study drug discontinuation for any reason is reported here.	From Day 1 to Week12
Secondary	Time to Study Drug Discontinuation Due to Lack of Efficacy or Progressive Disease.	Proportion of study drug discontinuation due to lack of efficacy or progressive disease was analyzed using Kaplan-Meier curves. Number of patients discontinuing study drug due to lack of efficacy or progressive disease is reported here.	From Day 1 to Week12
Secondary	Proportion of Patients Who Have Initiated Tapering of Glucocorticoids.	Please note no patients were treated with any systemic glucocorticoids at randomization. Hence no results available	From Week 2 to Week12
Secondary	Proportion of Patients That Have Decreased the Glucocorticoid Dose With at Least 50% From Baseline.	Please note no patients were treated with any systemic glucocorticoids at randomization. Hence no results available	From Week 2 to Week12
Secondary	Percentage Decrease of the Glucocorticoid Dose From Baseline.	Please note no patients were treated with any systemic glucocorticoids at randomization. Hence no results available	From Day 1 to Week12
Secondary	Proportion of Patients With at Least One Adverse Event.	All adverse events collected from start of study treatment up to 28 days after stopping study treatment.	From Day 1 to Week 16
Secondary	Proportion of Patients With at Least One Serious Adverse Event Including Death.	Serious adverse events (SAEs) will be collected from informed consent up to 28 days after stopping study treatment.	From Informed consent to Week 16
Secondary	Proportion of Patients With Macrophage Activation Syndrome (MAS).	Proportion of patients with Macrophage Activation Syndrome (MAS).	From Day 1 to Week 16
Secondary	Proportion of Patients With Antidrug Antibodies (ADA) Against Anakinra.	Proportion of patients with antidrug antibodies (ADA) against anakinra.	Week 2
Secondary	Proportion of Patients With Neutralizing Antibodies.	Confirmed ADA positive samples will be analyzed for the presence of neutralizing antibodies.	Week 2
Secondary	Anakinra Serum Pre-dose Concentrations.	Week 2 reported here.	Week 2
Secondary	Anakinra Serum Pharmacokinetic Parameters: Cmax,	PK parameters only available for 2 patients.	Week 12
Secondary	Anakinra Serum Pharmacokinetic Parameters, Tmax and T½	PK parameters only available for 2 patients	Week 12
Secondary	Anakinra Serum Pharmacokinetic Parameter: AUC 0-24 h	PK parameters only available for 2 patients	Week 12
Secondary	Anakinra Serum Pharmacokinetic Parameter: CL/F	Pharmacokinetic parameters only available for 2 patients	Week 12
Secondary	Anakinra Serum Pharmacokinetic Parameter: Vd/F	PK parameters only available for 2 patients	Week 12
Secondary	Change From Baseline in JADAS27.	Juvenile Arthritis Disease Activity Score (JADAS) includes 4 measures: physician global assessment of disease activity, patient or parent global assessment of overall well-being, 27 active joint count, and CRP. The JADAS27 includes the 27 joints. JADAS27 is calculated as the sum of its four components, physician global assessment of disease activity converted to cm from the VAS (0=no activity, 10=maximum activity); patient global assessment of well-being converted to cm from the VAS (0=very well, 10=very poor); active joint count (0-27); and CRP. Prior to calculation CRP is truncated to a 0 - 10 scale according to the following formula: (CRP (mg/l) -10)/10. Before calculation, CRP values <10 mg/l are converted to 10 and CRP values >110 mg/l are converted to 110. The JADAS27 tool yields a global score of 0-57.; Only results from Week 2 reported here.	Week 2
Secondary	Number of Days Off School or Work Due to Still's Disease.	Number of days off school or work due to Still's disease week 1-2.	Week 2
Secondary	Proportion of Patients With Inactive Disease.	Inactive disease is a composite of the following parameters: no joints with active arthritis, no fever, no rash, no serositis, no splenomegaly, no generalized lymphadenopathy attributable to Still's disease, CRP level within normal limits, physician's global assessment of disease activity score below 10 mm on a 100 mm VAS and a documented morning stiffness =15 minutes.	Week 12
Secondary	Change From Baseline in IL-6.	Only results from Week 2 reported here.	Week 2
Secondary	Change From Baseline in IL-18.	Only results from Week 2 reported here	Week 2
Secondary	Change From Baseline in Serum Calprotectin.	Change from baseline in serum calprotectin. Only results from Week 2 reported here	Week 2
Secondary	Change From Baseline in Neopterin.	Only results from Week 2 reported here	Week 2